Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)Jennifer L. Crombie, Marcelo C. Pasquini, Loretta J. Nastoupil et al.|Blood|2023Cited by 17
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistryMaría Silvina Odstrcil Bobillo, Matthew J. Frigault, David Bernasconi et al.|Blood|2024Cited by 7
Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)M. Lia Palomba, Marcelo C. Pasquini, Jennifer L. Crombie et al.|Transplantation and Cellular Therapy|2024Cited by 7
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistrySairah Ahmed, Jennifer L. Crombie, Avyakta Kallam et al.|Blood|2024Cited by 6
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D. Hunter, Manali Kamdar, Matthew A. Lunning et al.|Transplantation and Cellular Therapy|2025Cited by 3